Psychosocial effect of vitiligo: A comparison of vitiligo patients with “normal” control subjects, with psoriasis patients, and with patients with other pigmentary disorders

Porter, Judith R.; Beuf, Ann H.; Lerner, Aaron B.; Nordlund, James J.

doi:10.1016/s0190-9622(86)70160-6

Cited by 139 publications

(103 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many vitiligo patients are distressed, especially in relation with social encounters, or feel embarrassed when exposing the body [4,5,6]. Moreover, vitiligo patients may suffer from low self-esteem and poor body image, experience discrimination from others and feel stigmatized [2, 7, 8]. …”

Section: Introductionmentioning

confidence: 99%

Quality of Life and Stigmatization Profile in a Cohort of Vitiligo Patients and Effect of the Use of Camouflage

Ongenae¹,

Dierckxsens²,

Brochez³

et al. 2005

Dermatology

164

154

View full text Add to dashboard Cite

Background: Few studies have paid attention to the effects of treatment interventions on the psychosocial consequences of vitiligo. Objectives: To quantify and analyse the psychosocial benefit of the use of camouflage in vitiligo patients. Patients and Methods: 78 vitiligo patients completed the Dermatology Life Quality Index (DLQI) and an adapted stigmatization questionnaire, and 62 of them completed the DLQI after at least a 1-month use of camouflage. Results: The initial mean overall DLQI score (n = 78) is 6.9 (SD 5.6). The mean global stigmatization score is 38%. Disease extent and disease severity are strong predictors of the DLQI (p < 0.0001). Vitiligo on the face/head/neck substantially affects the DLQI, independently of degree of involvement. The mean DLQI score before and after use of camouflage (n = 62) is 7.3 (SD 5.6) and 5.9 (SD 5.2; p = 0.006). Mainly the high-scoring items ‘feelings of embarrassment and self consciousness’ and ‘choice of clothing’ improve. Predictors of improvement are higher DLQI scores (p = 0.0005) and higher total severity scores (p = 0.03). Conclusions: Camouflage can be recommended, particularly in patients with higher DLQI scores or self-assessed disease severity. Patients with minor involvement of the face benefit from camouflage.

show abstract

Section: Introductionmentioning

confidence: 99%

Quality of Life and Stigmatization Profile in a Cohort of Vitiligo Patients and Effect of the Use of Camouflage

Ongenae¹,

Dierckxsens²,

Brochez³

et al. 2005

Dermatology

164

154

View full text Add to dashboard Cite

show abstract

“…If even only a small proportion of patients with vitiligo are severely socially, psychologically or emotionally affected by the disorder, they nevertheless represent a large number of diseased individuals whose wellbeing should not be neglected. It has been reported that 75% of vitiligo patients estimate their appearance as moderately to severely intolerable, and a large proportion of them have low self-esteem, fear, anxiety stress and a feeling of shame in social interactions [2,3,[43][44][45][46].…”

Section: Discussionmentioning

confidence: 99%

Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study

Ruı́z-Argüelles

Garcı́a-Carrasco

Jimenez-Brito³

et al. 2013

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryFive patients with active disseminated vitiligo were given 1 g of a chimeric (murine/human) monoclonal antibody to CD20 in a single intravenous infusion and followed-up for 6 months. Three of the patients showed an overt clinical and histological improvement of the disease, one presented slight improvement and the remaining patient showed no changes. Improvement was neither associated with changes in laboratory parameters nor to a specific human leucocyte antigen D-related (HLA-DR) phenotype. We believe that these preliminary results are encouraging, and further clinical trials should be undertaken. An important aim should be the finding of a marker with a good response to this therapeutic approach.

show abstract

“…Besides, there are increased levels of various neuropeptides i.e. substances P and vasoactive intestinal polypeptide (VIP) in the psoriatic skin, alteration of skin texture and more disability in areas of daily activities and employment in psoriatic patients than that of vitiligo patients 5,15,18 In our point of view, the above finding might be due to secondary effects of psoriasis such as oozing and bleeding from skin, more discomfort and itching as well as more problems in adjusting to the discomfort of psoriasis than that of vitiligo patients. Moreover, as psoriasis produces more physical disabilities with cosmetic disfigurement in comparison to vitiligo as well as different aetiological aspect of the two diseases may explain this finding.…”

Section: Discussionmentioning

confidence: 99%

Psychiatric Morbidity in Psoriasis and Vitiligo in Two Tertiary Hospitals in Bangladesh

Rashid

Mullick

Jaigirdar

et al. 2011

Bangabandhu Sheikh Mujib Medical Univ J

View full text Add to dashboard Cite

Abstract:Background: Many of the established skin diseases give rise to psychiatric disorders notably psoriasis and vitiligo. In Bangladesh, no study has yet been reported on psychiatric morbidity among psoriasis and vitiligo patients. Objectives: The objective of the study was to see the psychiatric morbidities in two chronic skin diseases, psoriasis and vitiligo, in Bangladesh. Methods: This was a cross sectional, analytical and comparative study. It was conducted to see whether psychiatric morbidity was higher among patients with psoriasis than that of vitiligo. Specific types of psychiatric disorders were identified by consultant psychiatrist assigned as per criteria of (Diagnostic and Statistical Manual for Mental and Behavioural Disorders-Fourth Edition)DSM-IV among 50 patients with psoriasis and same number of patients with vitiligo and were compared. Study places were the Departments of Dermatology and Venereology, Bangabandhu Sheikh Mujib Medical University (BSMMU) and Dhaka Medical College Hospital (DMCH) in Dhaka city. Results: Among the two dermatological conditions, psychiatric disorders were found 25 (50%) in psoriatic patients and 12 (24%) that in vitiligo patients. The proportion of major depressive disorders (MDD) was higher among psoriasis patients 15(30.0%) compared to vitiligo patients 04(8.0%). However, no statistical difference was found between two groups of patients in terms of anxiety disorders (8% in psoriasis and 12% in vitiligo patients). In patients with psoriasis, MDD was found highest (30.0%) followed by anxiety disorders (8.0%), adjustment disorder (4.0%) and somatoform disorder not otherwise specified (2.0%). Whereas, among the vitiligo patients, anxiety disorder was found highest (12.0%) followed by MDD (8.0%). The Present study showed significant association of psychiatric morbidities in these two dermatological diseases (psoriasis and vitiligo) with the variables of the study population. Conclusion: It has been found in Bangladesh that the psychiatric morbidity is higher among the patients with psoriasis than vitiligo.

show abstract

Psychosocial effect of vitiligo: A comparison of vitiligo patients with “normal” control subjects, with psoriasis patients, and with patients with other pigmentary disorders

Cited by 139 publications

References 8 publications

Quality of Life and Stigmatization Profile in a Cohort of Vitiligo Patients and Effect of the Use of Camouflage

Quality of Life and Stigmatization Profile in a Cohort of Vitiligo Patients and Effect of the Use of Camouflage

Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study

Psychiatric Morbidity in Psoriasis and Vitiligo in Two Tertiary Hospitals in Bangladesh

Contact Info

Product

Resources

About